JUNSHI BIO (01877) issues 700 million yuan in technology innovation bonds.

19:48 21/08/2026

Junshi Bio (01877) announced that the third phase of its technological innovation bond for 2026 has been successfully issued, and the raised funds arrived on August 21, 2026. The total amount issued is 700 million yuan, with an interest rate of 2.55% and a term of 3 years.

JUNSHI BIO (01877) announced that the Company's third phase of the 2026 science and technology innovation bonds has been successfully issued, with the raised funds received on August 21, 2026. The total issuance amount is 700 million yuan, the issuance interest rate is 2.55%, and the term is 3 years.

JS GLOBAL LIFE (01691) announced its interim results, with a profit attributable to owners of the parent company of 9.419 million US dollars, returning to profitability compared to the same period last year.

Longdian Huaxin (FOIL.US): The copper foil "invisible champion" has landed on the New York Stock Exchange, with three barriers building its leading strength.

IMMUNEONCO-B (01541): The U.S. Food and Drug Administration has approved the IND application for the Phase Ib/II clinical trial of IMM0306 for the treatment of systemic lupus erythematosus.

Longdian Huaxin (FOIL.US): The copper foil "invisible champion" has landed on the New York Stock Exchange, with three barriers building its leading strength.

IMMUNEONCO-B (01541): The U.S. Food and Drug Administration has approved the IND application for the Phase Ib/II clinical trial of IMM0306 for the treatment of systemic lupus erythematosus.